Our study unveiled molecular mechanisms underlying GC metastasis driven by RASA1 mutations and Nf2 deficiency and proposed a novel therapeutic strategy involving combined inhibition of Bcl-2 family members and YAP for treatment of highly metastatic GC. The gene discussed is RASA1; the disease is gastric cancer.